Vaccines for Enteric Diseases

8-10 July 2015, The Royal College of Physicians of Edinburgh, Edinburgh, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 10th July 2015


Moderators: Umesh Parashar (CDC, Atlanta, Georgia, USA)

‘Rotavirus vaccine effectiveness in Zambia – Preliminary results from Lusaka Province’
Laura Beres, Lungowe Njobvu, Bertha Chibwe, Annika Kruuner, Cheryl Rudd, M. Brad Guffey, Jacqueline Tate, Umesh Parashar, Jeffrey Stringer and Roma Chilengi (Centre for Infectious Disease Research in Zambia, Lusaka, Zambia)

‘A Phase I/II descending age, double-blinded, randomized, placebo-controlled dose escalation study to examine the safety, tolerability and immunogenicity of the P2-VP8 subunit parenteral rotavirus vaccine in healthy South African toddlers and infants’
M.J. Groome 1,2, A. Koen 1,2, A. Hugo 1,2, L. Jose 1,2, S.A. Madhi 1,2, M. McNeal 3, N. Meyer 3, B. Phillips 3, N. Page 4, M. Power 5, A. Fix 5, J. Flores 5, J. Boslego 5 and S. Cryz 5 (1 Medical Research Council: University of the Witwatersrand, Johannesburg, South Africa; 2 Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa; 3 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; 4 National Institute for Communicable Diseases, Sandringham, South Africa; 5 PATH, Washington, DC, USA)

‘The “Performance of Oral Vaccines in Developing Countries (PROVIDE)” study: Insights into oral rotavirus vaccine underperformance’
B.D. Kirkpatrick, R. Haque, J. Mychaleckyj, M. Carmolli, D. Dickson, S.A. Diehl, U. Nayak, J. Ma, M. Lu, C. Naylor, E.R.Colgate and W.A. Petri Jr. (University of Vermont, Burlington, Vermont, USA)

‘Modeling the potential for vaccine-driven strain replacement following rotavirus vaccination in Belgium’
Virginia E. Pitzer 1, Joke Bilcke 2, Elisabeth Heylen 3, Mark Zeller 3, Forrest W. Crawford 1 and Jelle Matthijnssens 3 (1 Yale School of Public Health, New Haven, Connecticut, USA; 2 University of Antwerp, Antwerp, Belgium; 3 University of Leuven, Leuven, Belgium)

Coffee Break & Posters


Moderators: Duncan Steele (Bill & Melinda Gates Foundation, Seattle, Washington, USA)

‘Regulatory aspects of enteric vaccine development: A US FDA perspective’
Jon Daugherty (CBER/FDA, Silver Spring, Maryland, USA)

‘Environmental enteropathy, malnutrition and oral polio vaccine response’
Caitlin Naylor, Jennie Ma, Miao Lu, Mami Taniuchi, Eric Houpt, Uma Nayak, Joe Mychaleckyj, Ross Colgate, Marya Carmolli, Masud Alam, Rashidul Haque, Beth Kirkpatrick and William A. Petri, Jr., for the PROVIDE Study (University of Virginia, Charlottesville, Virginia, USA; University of Vermont, Burlington Vermont, USA; ICDDRB, Dhaka, Bangladesh)

‘Typhoid vaccination in the US military’
Chad K. Porter, Tia Sorrel, Indrani Mitra and Mark S. Riddle (Naval Medical Research Center, Silver Spring, Maryland, USA)

‘Co-administration of oral polio vaccines interferes with Rotarix immunogenicity in rural Bangladesh’
D. Emperador 1, D. Velasquez 1, C. Estivariz 2, B. Lopman 1, B. Jiang 1, U. Parashar 1, A. Anand 2 and K. Zaman 3 (1 Division of Viral Diseases and 2 Global Immunization Division, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA; 3 International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh)

‘Typhoid fever protein capsular matrix vaccine: Pathway to phase 1 clinical trial’
Kevin Killeen (Matrivax Inc., Boston, Massachusetts, USA)

Lunch Break & Posters


Moderators: Florian Marks (International Vaccine Institute, Seoul, Korea) and John Clemens (International Centre for Diarrhoea Disease Research, Dhaka, Bangladesh)

‘Causes of prior inconsistency of protective efficacy and rationale for renewed clinical evaluation of Salmonella Typhi Ty21a expressing Shigella sonnei form 1 O-antigen’
Dennis J. Kopecko 1, Stanley Cryz 2, Anu Kantele 3, Kim Lee Sim 1 and Stephen L. Hoffman 1 (1 Protein Potential LLC, Rockville, Maryland, USA, 2 PATH, Washington DC, USA, 3 Helsinki Hospital, Helsinki, Finland)

‘Prevention of shigellosis during infancy through maternal immunity and vaccination early life’
Shannon J. Heine, Olga L. Franco-Mahecha, Eileen M.Barry and Marcela F. Pasetti (University of Maryland School of Medicine, Baltimore, Maryland, USA)

‘Combinatorial effects of secretory IgA on Vibrio cholerae virulence and fitness in the intestinal lumen’

Kara J. Levinson, Magdia De Jesus, Samantha Giffen, Danielle Hindes and Nicholas J. Mantis (Wadsworth Center, New York State Department of Health, Albany, New York, USA / University at Albany, Albany, New York, USA)

‘Low cost optimized oral cholera vaccine’
Davinder Gill, Zimra Israel, Stefan Karlsson, Michael Lebens and Jan Holmgren (Hilleman Labortaories Private Ltd., New Delhi, India/University of Gothenburg, Gothenburg, Sweden)

Tea Break & Departure

* This final programme is correct at the time of printing. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.


VED 2015 Sponsors

  • Aldevron
  • Eveliqure
  • hVIVO
  • BioVaxx
  • Takeda
  • GlycoVaxyn
  • Matrivax
  • Sanofi Pasteur
  • PATH
  • Vaccine Research Center

VED 2015 Downloads

VED 2015 Leaflet

VED 2015 Mailing List

E-mail Address
What is 6+3-1?